Concurrent cisplatin chemotherapy with intensity‐modulated radiotherapy followed by consolidation chemotherapy in early‐stage cervical cancer patients with high‐risk factors after radical hysterectomy
Journal of Obstetrics and Gynaecology Research · 2025
DOI: 10.1111/jog.16346 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2025. Verfasst von Si-Tong Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Cisplatin, Radiotherapy, Intensity-Modulated, Chemoradiotherapy. Die Arbeit nennt 27 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
To evaluate the efficacy and toxicity of consolidation chemotherapy (C‐CT) following concurrent cisplatin chemotherapy combined with intensity‐modulated radiotherapy (IMRT) in patients with early‐stage cervical cancer who present high‐risk factors (HRFs).
Methods
Between 2013 and 2023, a total of 190 women were included in this retrospective study. Among these, 82 patients received postoperative concurrent chemoradiotherapy (CCRT) with weekly cisplatin and IMRT (45.0–50.4 Gy), followed by C‐CT, while 108 patients received CCRT alone. A propensity score matching (PSM) was performed with a ratio of 1:1. Clinical parameters, overall survival (OS), and relapse‐free survival (RFS) were analyzed for both groups.
Results
The median follow‐up duration was 50.2 months. The 4‐year OS rates were 88.7% in the C‐CT group and 87.9% in the CCRT‐only group ( p = 0.886). The 4‐year RFS rates were 76.3% for the C‐CT group and 80.5% for the CCRT‐only group ( p = 0.289). In patients with three or more positive lymph nodes, C‐CT was associated with significantly improved OS compared to the CCRT‐only group (HR 0.14, 95% CI 0.02–0.88, p = 0.036), while RFS showed no significant difference (HR 0.80, 95% CI 0.27–2.32, p = 0.676). However, the incidence of grade 3/4 hematologic toxicity was higher in the C‐CT group (16.8% vs. 1.7%, p = 0.009).
Conclusions
Our study found that C‐CT following concurrent cisplatin chemotherapy with IMRT did not confer additional benefits over CCRT alone in the majority of early‐stage cervical cancer patients with HRFs, except in those with three or more positive lymph nodes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Gynecological Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Gui-Fen Ma, Gen-Lai Lin
Zitieren
APA
Wang, S. T., Ma, G. F., Xiao, C. L., Shi, T. Y., Xiang, L. B., Ma, L., & Lin, G. L. (2025). Concurrent cisplatin chemotherapy with intensity‐modulated radiotherapy followed by consolidation chemotherapy in early‐stage cervical cancer patients with high‐risk factors after radical hysterectomy. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.16346
Vancouver
Wang ST, Ma GF, Xiao CL, Shi TY, Xiang LB, Ma L, et al. Concurrent cisplatin chemotherapy with intensity‐modulated radiotherapy followed by consolidation chemotherapy in early‐stage cervical cancer patients with high‐risk factors after radical hysterectomy. Journal of Obstetrics and Gynaecology Research. 2025. doi:10.1111/jog.16346
BibTeX
@article{Wang2025,
author = {Wang, Si-Tong and Ma, Gui-Fen and Xiao, Chun-Li and Shi, Ting-Yan and Xiang, Li-Bing and Ma, Li and Lin, Gen-Lai},
title = {Concurrent cisplatin chemotherapy with intensity‐modulated radiotherapy followed by consolidation chemotherapy in early‐stage cervical cancer patients with high‐risk factors after radical hysterectomy},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2025},
doi = {10.1111/jog.16346}
}
EUVIMED